Pathologist-recommended molecular testing in endometrial cancer: A single-institution experience highlighting the recognition of POLE-Mutated carcinomas in post-menopausal and advanced stage patients, immunohistochemical pitfalls, and other clinically significant findings.
- DOI
- 10.1016/j.humpath.2026.106237
- Published
- 2026 Aug 18
- Container
- Human pathology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.humpath.2026.106237,
title = {Pathologist-recommended molecular testing in endometrial cancer: A single-institution experience highlighting the recognition of POLE-Mutated carcinomas in post-menopausal and advanced stage patients, immunohistochemical pitfalls, and other clinically significant findings.},
author = {Mills AM and Vidis L and Carlson DK and Crawford MP and Glasgow-Austin A and Smith VL and Ring KL and Alzayadneh E},
year = {2026},
journal = {Human pathology},
doi = {10.1016/j.humpath.2026.106237},
url = {https://doi.org/10.1016/j.humpath.2026.106237}
}RIS
TY - JOUR TI - Pathologist-recommended molecular testing in endometrial cancer: A single-institution experience highlighting the recognition of POLE-Mutated carcinomas in post-menopausal and advanced stage patients, immunohistochemical pitfalls, and other clinically significant findings. AU - Mills AM AU - Vidis L AU - Carlson DK AU - Crawford MP AU - Glasgow-Austin A AU - Smith VL AU - Ring KL AU - Alzayadneh E PY - 2026 JO - Human pathology DO - 10.1016/j.humpath.2026.106237 UR - https://doi.org/10.1016/j.humpath.2026.106237 ER -
APA
AM, M., L, V., DK, C., MP, C., A, G., VL, S., KL, R., & E, A. (2026). Pathologist-recommended molecular testing in endometrial cancer: A single-institution experience highlighting the recognition of POLE-Mutated carcinomas in post-menopausal and advanced stage patients, immunohistochemical pitfalls, and other clinically significant findings.. Human pathology. https://doi.org/10.1016/j.humpath.2026.106237
Source records
- pubmed · retrieved 2026-09-26T03:02:48.235Z